Altimmune raises $75 million through registered direct offering to fund Phase 3 trial of pemvidutide for MASH treatment and advance its liver disease therapy pipeline.
Altimmune shares jump 24% after FDA grants breakthrough therapy designation for pemvidutide, a promising treatment for MASH liver disease showing significant trial results.
Altimmune (ALT) reports 48-week results for pemvidutide in MASH trial, showing continued weight loss and liver fibrosis improvements, though some measures weakened from earlier data.
Pharma giant Roche bought 89bio for up to $3.5B. The focus is pegozafermin, a promising drug for treating MASH (severe fatty liver disease). This deal positions Roche to transform care in metabolic diseases. Shares of 89bio surged 85% on Thursday.
The FDA accepted non-invasive Liver Stiffness Measurement as a surrogate endpoint for MASH clinical trials, replacing biopsies. This key decision accelerates MASH drug development by enabling safer monitoring, speeding recruitment, and predicting patient outcomes.
